Accelerate CNS and Stroke Research with a Human-Relevant BBB Chip Model
The blood–brain barrier remains one of the most significant challenges in CNS drug development. Traditional in vitro models often fail to accurately predict drug transport, permeability, and barrier responses, leading to costly delays and poor clinical translation.
Download our case study to discover how Ace Therapeutics' Blood–Brain Barrier (BBB) Chip Model provides a physiologically relevant platform for evaluating drug transport, barrier integrity, and therapeutic delivery across the BBB.
Download this case study to see:
Whether you are developing small molecules, biologics, antibodies, or novel delivery systems, this case study provides valuable insights into leveraging BBB-on-a-chip technology for more informed decision-making.
A systematic introduction to Ace Therapeutics' preclinical stroke research capabilities and cutting-edge technology platforms.
Our models combine primary endothelial and glial co-culture systems to simulate the structural and functional integrity of the BBB under both normal and ischemic conditions.
Our customized in vitro models of stroke and advanced cell-based assay platform accelerate the discovery of novel stroke therapies.
The OGD model is achieved by replacing the oxygen- and glucose-rich medium with an oxygen- and glucose-deprived medium equilibrated with nitrogen.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.